# US 2012/0251499 A1 · Method for diagnosis/prognosis of cancers using an epigenetic marker consisting of a specific single cpg site in ttp promoter and treatment of cancers by regulating its epigenetic status

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251499 A1
- Document ID: US20120251499A1
- Status: Published application
- Kind: A1
- Application number: 13/514,913
- Filed: 2010-09-08
- Published: 2012-10-04
- Earliest claimed: 2009-12-11
- Assignees: Korea Research Institute of Bioscience and Biotechnology
- Inventors: Young Il Yeom; Bo Hwa Sohn; In Young Park; Jung Ju Lee; Yejin Jang; Suk-jin Yang; Kyung Chan Park; Hyang-sook Yoo; Jong Young Choi
- Web page: https://patentgrep.com/patent/US20120251499A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 35/00: Antineoplastic agents
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12Q 2600/154: Methylation markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method for treatment of liver cancer comprising a step of administering to a subject having liver cancer a methylation inhibitor of a cytosine residue, which inhibits methylation of the 32nd nucleotide of the nucleic acid sequence represented by SEQ. ID. NO. 41.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the methylation inhibitor 5-Aza-2-deoxycytidine (AzadC, Decitabine), 5-Azacytidine (AzaC), Zebularine {1-(β-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one} or recombinant virus containing siRNA or shRNA targeting DNMT1 and DMNT3A.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the methylation inhibitor comprises an inhibitor of expressions, activities or interactions of proteins continuously suppressing TTP transcription by binding to the methylated 32nd cytosine residue and maintaining the methylation in that site.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the inhibitor of expressions, activities or interactions of the proteins continuously suppressing TTP transcription by binding to the methylated 32nd cytosine residue and maintaining the methylation in that site comprises: material inhibiting formation and binding of MECP2/c-Ski/DNMT3A (DNA methyltransferase 3A) confirmed as a major transcriptional inhibitor complex inducing methylation of the 32nd cytosine residue such as siRNAs to MECP2, c-Ski, DNMT3A, and SMAD2/3; recombinant viruses carrying antisense RNA, shRNA, or ribozyme sequences to these genes; small-molecular materials, natural substances, peptides, or derivatives thereof suppressing the interaction between the proteins encoded by these genes.

### Claim 21 (depends on 19)

The method according to claim 19, further comprising administering either simultaneously or sequentially an activator of TGFβ1 or TGFβ1 pathway.

### Claim 22

A method for diagnosis of liver cancer, comprising steps of:
1) detecting methylation of the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41 in the genomic DNA isolated from the clinical sample obtained from a liver cancer suspicious subject; and
2) predicting the likelihood and prognosis of liver cancer when methylation is detected in step 1).

### Claim 23 (depends on 22)

The method according to claim 22, wherein the step of detecting methylation is performed using a probe or a primer set which is selected from the polynucleotide represented by SEQ. ID. NO. 41 in which the 32nd nucleotide is cytosine, and which is capable of detecting methylation of the cytosine residue.

### Claim 24 (depends on 23)

The method according to claim 23, further comprising converting unmethylated cytosine residues to uracil in the genomic DNA prior to detecting methylation.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the probe is complementary to the sense and/or antisense oligonucleotide for 15˜30 bp contiguous sequence containing the 32nd cytosine residue.

### Claim 26 (depends on 23)

The method according to claim 23, wherein the primer set is comprised of the sense and/or antisense oligonucleotide of 15˜50 bp in length capable of amplifying the oligonucleotide containing the 32nd nucleotide.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the primer set is selected from the group consisting of:
1) primer set 1 comprised of the sense primer represented by SEQ. ID. NO. 5 and the antisense primer represented by SEQ. ID. NO. 6;
2) primer set 2 comprised of the sense primer represented by SEQ. ID. NO. 11 and the antisense primer represented by SEQ. ID. NO. 12; and
3) primer set 3 comprising of the primer set 2 and the primer represented by SEQ. ID. NO. 13.

### Claim 28

A method for evaluating prognosis of a liver cancer, comprising steps of:
1) detecting methylation of the 32″ residue of the nucleic acid sequence represented by SEQ. ID. NO. 41 in the genomic DNA isolated from the clinical sample obtained from a subject whose liver cancer have been surgically removed; and
2) predicting that liver cancer cells were all eliminated if methylation has not been detected in step 1).

### Claim 29 (depends on 28)

The method according to claim 28, wherein the step of detecting methylation is performed using a probe or a primer set which is selected from the polynucleotide represented by SEQ. ID. NO. 41 in which the 32nd nucleotide is cytosine, and which is capable of detecting methylation of the cytosine residue.

### Claim 30 (depends on 29)

The method according to claim 29, further comprising converting unmethylated cytosine residues to uracil in the genomic DNA prior to detecting methylation.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the probe is complementary to a sense and/or antisense oligonucleotide of 15˜30 bp in length containing the 32nd cytosine residue.

### Claim 32 (depends on 29)

The method according to claim 29, wherein the primer set is composed of a sense and/or antisense oligonucleotide of 15˜50 bp in length capable of amplifying the oligonucleotide containing the 32nd nucleotide.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the primer set is selected from the group consisting of:
1) primer set 1 comprising the sense primer represented by SEQ. ID. NO. 5 and the antisense primer represented by SEQ. ID. NO. 6;
2) primer set 2 comprising the sense primer represented by SEQ. ID. NO. 11 and the antisense primer represented by SEQ. ID. NO. 12; and
3) primer set 3 comprising the primer set 2 and the primer represented by SEQ. ID. NO. 13.
